Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma
Status:
Completed
Trial end date:
2017-03-23
Target enrollment:
Participant gender:
Summary
This study aimed to investigate the clinical benefit contribution and safety of nimotuzumab
to the standard combined treatment for patients with newly diagnosed glioblastoma.